The Israel Institute for Biological Research (IIBR) (see here previously) has signed an agreement with Israeli-founded NRx Pharmaceuticals. NRx will complete Phase 2 / 3 trials and commercialize IIBR’s “BriLife” COVID vaccine. Clinical trials will be completed in the Ukraine, Georgia and Israel.
https://www.israelnationalnews.com/News/News.aspx/309717
https://en.globes.co.il/en/article-nrx-to-commercialize-israels-covid-19-vaccine-1001377983